CHMP Favors Kadcyla Approval in EU for Certain HER2-positive Early Breast Cancer Patients
News
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive ... Read more